抗糖尿病药物标对卵巢癌的亚型特定因果作用:孟德尔随机化和局部化证据
Enyu Tang1, Jia Zeng1, Xinlong Shi2
1Department of Gynecology Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
International journal of women's health
|March 16, 2026
概括
抗糖尿病药物标显示出亚型特定的与卵巢癌 (OC) 风险和生存率的关联. 这表明,这些药物有可能重新用于治疗多种OC亚型,从而改善患者的治疗结果.
科学领域:
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 卵巢癌 (OC) 的死亡率高,治疗方法有限,因此需要准确治疗的新型治疗点.
- 抗糖尿病药物标是扩大OC治疗选择在各种亚型的潜在途径.
研究的目的:
- 调查抗糖尿病药物标基因与不同卵巢癌 (OC) 亚型的风险/生存之间的关联.
- 探索基于遗传关联的抗糖尿病药物重新用于OC治疗的潜力.
主要方法:
- 利用大规模数据集的综合分析 (卵巢癌协会联盟,eQTLGen,GTEx).
- 采用了两样本的孟德尔随机化 (MR),基于数据的总结MR和局部化分析.
- 使用阳性对照,复制,MR-Egger,Bonferroni校正和MR-PRESSO异常值测试的验证结果.
主要成果:
- 确定了抗糖尿病药物标和OC风险之间的显著亚型特定关联 (例如,AKR1A1具有低级血清性OC,HMGCR/KCNJ11具有清晰细胞OC).
- 发现了粘膜OC (ITGAL,AKR1B1) 和子宫内膜OC (AKR1A1,ITGAL) 的相关性.
- 观察到DPP4和高度血清性OC存活率之间的联系.
结论:
- 在抗糖尿病标和OC之间的遗传联系中显示出显著的亚型特定异质性.
- 这些发现支持了代谢对OC进展的作用,并建议将药物重新用于量身定制的亚型特定疗法.
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K